NEW YORK, Dec. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
What are the commercial prospects for antibacterial treatments? Visiongain's report shows you potential revenue values to 2022. Find data, forecasts and discussions.
Discover sales predictions at world market, therapeutic class, product and national levels to 2022. Our report gives you business research, analysis and opinion for the treatment of bacterial infections.
How will 20 leading products - including Levaquin, Zyvox, Avelox, Augmentin, Zosyn, Merrem, Cubicin, Primaxin and Cravit - perform to 2022? You can find potential revenues, with discussions.
Also, receive forecast values for cephalosporin, penicillin, fluoroquinolone, macrolide and carbapenem submarkets. We analyse other agents too. See possible sales trends for antibiotics from 2012.
This study discusses Pfizer, Merck, GSK, Cubist, Abbott, Bayer and other pharmaceutical companies. Receive analyses for anti-infective agents in human healthcare, including hospital-acquired infections.
What does the future hold? With its R&D pipeline, the antimicrobial drug industry has potential for improved treatment of bacterial diseases. Bacteria still pose a great threat, with antibiotic resistance staying a challenge in clinical practice.
Visiongain's report provides data, analysis and opinion a
Copyright©2010 PR Newswire.
All rights reserved